Abeona launches pivotal study of RDEB gene-corrected cell therapy

Abeona Therapeutics (ABEO -4.3%) initiates a randomized Phase 3 clinical trial, VIITAL, evaluating gene-corrected cell therapy EB-101 in up to 15 patients with a rare inherited skin blistering disorder called recessive dystrophic epidermolysis bullosa (RDEB).

The primary endpoint is the proportion of wounds with greater than 50% healing at month 3 compared to untreated wound sites on the same patient.

Dosing should commence this quarter.

https://seekingalpha.com/news/3531419-abeona-launches-pivotal-study-of-rdeb-gene-corrected-cell-therapy